-
1
-
-
84867901553
-
The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes
-
Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA, The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012 9 658 670. doi: 10.1038/nrcardio.2012.131
-
(2012)
Nat Rev Cardiol
, vol.9
, pp. 658-670
-
-
Martin, J.F.1
Kristensen, S.D.2
Mathur, A.3
Grove, E.L.4
Choudry, F.A.5
-
2
-
-
79955706734
-
The hemostatic system as a modulator of atherosclerosis
-
Borissoff JI, Spronk HM, ten Cate H, The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011 364 1746 1760. doi: 10.1056/NEJMra1011670
-
(2011)
N Engl J Med
, vol.364
, pp. 1746-1760
-
-
Borissoff, J.I.1
Spronk, H.M.2
Ten Cate, H.3
-
3
-
-
84871505285
-
Thrombosis as an intravascular effector of innate immunity
-
Engelmann B, Massberg S, Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013 13 34 45. doi: 10.1038/nri3345
-
(2013)
Nat Rev Immunol
, vol.13
, pp. 34-45
-
-
Engelmann, B.1
Massberg, S.2
-
4
-
-
80155193100
-
Platelets in atherosclerosis
-
Lievens D, von Hundelshausen P, Platelets in atherosclerosis. Thromb Haemost 2011 106 827 838. doi: 10.1160/TH11-08-0592
-
(2011)
Thromb Haemost
, vol.106
, pp. 827-838
-
-
Lievens, D.1
Von Hundelshausen, P.2
-
6
-
-
33846118743
-
Platelets as immune cells: Bridging inflammation and cardiovascular disease
-
von Hundelshausen P, Weber C, Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007 100 27 40. doi: 10.1161/01.RES.0000252802.25497.b7
-
(2007)
Circ Res
, vol.100
, pp. 27-40
-
-
Von Hundelshausen, P.1
Weber, C.2
-
7
-
-
84973495062
-
Immune-mediated and lipid-mediated platelet function in atherosclerosis
-
Ahmadsei M, Lievens D, Weber C, von Hundelshausen P, Gerdes N, Immune-mediated and lipid-mediated platelet function in atherosclerosis. Curr Opin Lipidol 2015 26 438 448. doi: 10.1097/MOL.0000000000000212
-
(2015)
Curr Opin Lipidol
, vol.26
, pp. 438-448
-
-
Ahmadsei, M.1
Lievens, D.2
Weber, C.3
Von Hundelshausen, P.4
Gerdes, N.5
-
8
-
-
0037231665
-
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E
-
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K, Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003 9 61 67. doi: 10.1038/nm810
-
(2003)
Nat Med
, vol.9
, pp. 61-67
-
-
Huo, Y.1
Schober, A.2
Forlow, S.B.3
Smith, D.F.4
Hyman, M.C.5
Jung, S.6
Littman, D.R.7
Weber, C.8
Ley, K.9
-
9
-
-
0037240588
-
A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo
-
Massberg S, Gawaz M, Grüner S, Schulte V, Konrad I, Zohlnhöfer D, Heinzmann U, Nieswandt B, A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003 197 41 49
-
(2003)
J Exp Med
, vol.197
, pp. 41-49
-
-
Massberg, S.1
Gawaz, M.2
Grüner, S.3
Schulte, V.4
Konrad, I.5
Zohlnhöfer, D.6
Heinzmann, U.7
Nieswandt, B.8
-
10
-
-
24044440435
-
Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: An in vivo study in mice lacking glycoprotein IIb
-
Massberg S, Schürzinger K, Lorenz M, Konrad I, Schulz C, Plesnila N, Kennerknecht E, Rudelius M, Sauer S, Braun S, Kremmer E, Emambokus NR, Frampton J, Gawaz M, Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005 112 1180 1188. doi: 10.1161/CIRCULATIONAHA.105.539221
-
(2005)
Circulation
, vol.112
, pp. 1180-1188
-
-
Massberg, S.1
Schürzinger, K.2
Lorenz, M.3
Konrad, I.4
Schulz, C.5
Plesnila, N.6
Kennerknecht, E.7
Rudelius, M.8
Sauer, S.9
Braun, S.10
Kremmer, E.11
Emambokus, N.R.12
Frampton, J.13
Gawaz, M.14
-
11
-
-
27144539508
-
Platelets express functional Toll-like receptor-4.
-
Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P, Platelets express functional Toll-like receptor-4. Blood 2005 106 2417 2423. doi: 10.1182/blood-2005-03-0916
-
(2005)
Blood
, vol.106
, pp. 2417-2423
-
-
Andonegui, G.1
Kerfoot, S.M.2
McNagny, K.3
Ebbert, K.V.4
Patel, K.D.5
Kubes, P.6
-
12
-
-
84862837590
-
GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity
-
Placke T, Salih HR, Kopp HG, GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol 2012 189 154 160. doi: 10.4049/jimmunol.1103194
-
(2012)
J Immunol
, vol.189
, pp. 154-160
-
-
Placke, T.1
Salih, H.R.2
Kopp, H.G.3
-
13
-
-
0037877918
-
CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation
-
Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ, CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003 92 1041 1048. doi: 10.1161/01.RES.0000070111.98158.6C
-
(2003)
Circ Res
, vol.92
, pp. 1041-1048
-
-
Inwald, D.P.1
McDowall, A.2
Peters, M.J.3
Callard, R.E.4
Klein, N.J.5
-
14
-
-
84944681535
-
Regulation of atherosclerotic plaque inflammation
-
Bäck M, Weber C, Lutgens E, Regulation of atherosclerotic plaque inflammation. J Intern Med 2015 278 462 482. doi: 10.1111/joim.12367
-
(2015)
J Intern Med
, vol.278
, pp. 462-482
-
-
Bäck, M.1
Weber, C.2
Lutgens, E.3
-
15
-
-
70350447306
-
The multi-functionality of CD40L and its receptor CD40 in atherosclerosis
-
Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E, The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009 102 206 214. doi: 10.1160/TH09-01-0029
-
(2009)
Thromb Haemost
, vol.102
, pp. 206-214
-
-
Lievens, D.1
Eijgelaar, W.J.2
Biessen, E.A.3
Daemen, M.J.4
Lutgens, E.5
-
16
-
-
2642608661
-
Reduction of atherosclerosis in mice by inhibition of CD40 signalling
-
Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P, Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998 394 200 203. doi: 10.1038/28204
-
(1998)
Nature
, vol.394
, pp. 200-203
-
-
Mach, F.1
Schönbeck, U.2
Sukhova, G.K.3
Atkinson, E.4
Libby, P.5
-
17
-
-
0032740818
-
Requirement for CD154 in the progression of atherosclerosis
-
Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA, Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999 5 1313 1316. doi: 10.1038/15271
-
(1999)
Nat Med
, vol.5
, pp. 1313-1316
-
-
Lutgens, E.1
Gorelik, L.2
Daemen, M.J.3
De Muinck, E.D.4
Grewal, I.S.5
Koteliansky, V.E.6
Flavell, R.A.7
-
18
-
-
0034691040
-
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
-
Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ, Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 2000 97 7464 7469
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 7464-7469
-
-
Lutgens, E.1
Cleutjens, K.B.2
Heeneman, S.3
Koteliansky, V.E.4
Burkly, L.C.5
Daemen, M.J.6
-
19
-
-
77149136451
-
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile
-
Lutgens E, Lievens D, Beckers L, Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010 207 391 404. doi: 10.1084/jem.20091293
-
(2010)
J Exp Med
, vol.207
, pp. 391-404
-
-
Lutgens, E.1
Lievens, D.2
Beckers, L.3
-
20
-
-
0034691108
-
Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice
-
Schönbeck U, Sukhova GK, Shimizu K, Mach F, Libby P, Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000 97 7458 7463
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 7458-7463
-
-
Schönbeck, U.1
Sukhova, G.K.2
Shimizu, K.3
Mach, F.4
Libby, P.5
-
21
-
-
0036140664
-
CD40-CD40L interactions in atherosclerosis
-
Lutgens E, Daemen MJ, CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002 12 27 32
-
(2002)
Trends Cardiovasc Med
, vol.12
, pp. 27-32
-
-
Lutgens, E.1
Daemen, M.J.2
-
22
-
-
84856686739
-
Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke
-
Lukasik M, Dworacki G, Kufel-Grabowska J, Watala C, Kozubski W, Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke. Thromb Haemost 2012 107 346 355. doi: 10.1160/TH11-05-0345
-
(2012)
Thromb Haemost
, vol.107
, pp. 346-355
-
-
Lukasik, M.1
Dworacki, G.2
Kufel-Grabowska, J.3
Watala, C.4
Kozubski, W.5
-
23
-
-
0035856535
-
Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia
-
Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG, Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001 104 2395 2400
-
(2001)
Circulation
, vol.104
, pp. 2395-2400
-
-
Garlichs, C.D.1
John, S.2
Schmeisser, A.3
Eskafi, S.4
Stumpf, C.5
Karl, M.6
Goppelt-Struebe, M.7
Schmieder, R.8
Daniel, W.G.9
-
24
-
-
0037456769
-
Soluble CD40 ligand in acute coronary syndromes
-
CAPTURE Study Investigators
-
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, CAPTURE Study Investigators Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003 348 1104 1111. doi: 10.1056/NEJMoa022600
-
(2003)
N Engl J Med
, vol.348
, pp. 1104-1111
-
-
Heeschen, C.1
Dimmeler, S.2
Hamm, C.W.3
Van Den Brand, M.J.4
Boersma, E.5
Zeiher, A.M.6
Simoons, M.L.7
-
25
-
-
0035818509
-
Soluble CD40L and cardiovascular risk in women
-
Schönbeck U, Varo N, Libby P, Buring J, Ridker PM, Soluble CD40L and cardiovascular risk in women. Circulation 2001 104 2266 2268
-
(2001)
Circulation
, vol.104
, pp. 2266-2268
-
-
Schönbeck, U.1
Varo, N.2
Libby, P.3
Buring, J.4
Ridker, P.M.5
-
26
-
-
0041315652
-
Soluble CD40L: Risk prediction after acute coronary syndromes
-
Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U, Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003 108 1049 1052. doi: 10.1161/01.CIR.0000088521.04017.13
-
(2003)
Circulation
, vol.108
, pp. 1049-1052
-
-
Varo, N.1
De Lemos, J.A.2
Libby, P.3
Morrow, D.A.4
Murphy, S.A.5
Nuzzo, R.6
Gibson, C.M.7
Cannon, C.P.8
Braunwald, E.9
Schönbeck, U.10
-
27
-
-
0038580675
-
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones
-
Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U, Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003 107 2664 2669. doi: 10.1161/01.CIR.0000074043.46437.44
-
(2003)
Circulation
, vol.107
, pp. 2664-2669
-
-
Varo, N.1
Vicent, D.2
Libby, P.3
Nuzzo, R.4
Calle-Pascual, A.L.5
Bernal, M.R.6
Fernández-Cruz, A.7
Veves, A.8
Jarolim, P.9
Varo, J.J.10
Goldfine, A.11
Horton, E.12
Schönbeck, U.13
-
28
-
-
84882797420
-
The CD40/CD40L system: A new therapeutic target for disease
-
Zhang B, Wu T, Chen M, Zhou Y, Yi D, Guo R, The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett 2013 153 58 61. doi: 10.1016/j.imlet.2013.07.005
-
(2013)
Immunol Lett
, vol.153
, pp. 58-61
-
-
Zhang, B.1
Wu, T.2
Chen, M.3
Zhou, Y.4
Yi, D.5
Guo, R.6
-
29
-
-
26244443483
-
Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: Results from the Dallas Heart Study
-
de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA, Peshock R, Libby P, Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005 25 2192 2196. doi: 10.1161/01.ATV.0000182904.08513.60
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, pp. 2192-2196
-
-
De Lemos, J.A.1
Zirlik, A.2
Schönbeck, U.3
Varo, N.4
Murphy, S.A.5
Khera, A.6
McGuire, D.K.7
Stanek, G.8
Lo, H.S.9
Nuzzo, R.10
Morrow, D.A.11
Peshock, R.12
Libby, P.13
-
30
-
-
24644496796
-
The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers
-
FATE Investigators
-
Verma S, Wang CH, Li SH, Lonn E, Charbonneau F, Title LM, Anderson TJ, FATE Investigators The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 2005 182 361 365. doi: 10.1016/j.atherosclerosis.2005.02.019
-
(2005)
Atherosclerosis
, vol.182
, pp. 361-365
-
-
Verma, S.1
Wang, C.H.2
Li, S.H.3
Lonn, E.4
Charbonneau, F.5
Title, L.M.6
Anderson, T.J.7
-
31
-
-
84924415569
-
Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction
-
Liebetrau C, Hoffmann J, Dörr O, Gaede L, Blumenstein J, Biermann H, Pyttel L, Thiele P, Troidl C, Berkowitsch A, Rolf A, Voss S, Hamm CW, Nef H, Möllmann H, Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res 2015 116 867 875. doi: 10.1161/CIRCRESAHA.116.304653
-
(2015)
Circ Res
, vol.116
, pp. 867-875
-
-
Liebetrau, C.1
Hoffmann, J.2
Dörr, O.3
Gaede, L.4
Blumenstein, J.5
Biermann, H.6
Pyttel, L.7
Thiele, P.8
Troidl, C.9
Berkowitsch, A.10
Rolf, A.11
Voss, S.12
Hamm, C.W.13
Nef, H.14
Möllmann, H.15
-
32
-
-
33744548144
-
Is there more than C-reactive protein and fibrinogen? the prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease
-
Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van Engelshoven JM, Daemen MJ, Nelemans PJ, Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2006 187 18 25. doi: 10.1016/j.atherosclerosis.2005.11.005
-
(2006)
Atherosclerosis
, vol.187
, pp. 18-25
-
-
Lobbes, M.B.1
Lutgens, E.2
Heeneman, S.3
Cleutjens, K.B.4
Kooi, M.E.5
Van Engelshoven, J.M.6
Daemen, M.J.7
Nelemans, P.J.8
-
33
-
-
33750607885
-
Influence of pre-Analytical and analytical factors on soluble CD40L measurements
-
Varo N, Nuzzo R, Natal C, Libby P, Schönbeck U, Influence of pre-Analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 2006 111 341 347. doi: 10.1042/CS20060047
-
(2006)
Clin Sci (Lond)
, vol.111
, pp. 341-347
-
-
Varo, N.1
Nuzzo, R.2
Natal, C.3
Libby, P.4
Schönbeck, U.5
-
34
-
-
84885319679
-
Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease
-
Lee R, Antonopoulos AS, Alexopoulou Z, Margaritis M, Kharbanda RK, Choudhury RP, Antoniades C, Channon KM, Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease. Int J Cardiol 2013 168 1648 1650. doi: 10.1016/j.ijcard.2013.03.019
-
(2013)
Int J Cardiol
, vol.168
, pp. 1648-1650
-
-
Lee, R.1
Antonopoulos, A.S.2
Alexopoulou, Z.3
Margaritis, M.4
Kharbanda, R.K.5
Choudhury, R.P.6
Antoniades, C.7
Channon, K.M.8
-
35
-
-
84924126063
-
Revisiting the role of sCD40L as an inflammatory biomarker in a clinical model of acute myocardial infarction
-
Lee R, Revisiting the role of sCD40L as an inflammatory biomarker in a clinical model of acute myocardial infarction. Circ Res 2015 116 e26. doi: 10.1161/CIRCRESAHA.114.305930
-
(2015)
Circ Res
, vol.116
, pp. e26
-
-
Lee, R.1
-
36
-
-
78549272749
-
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis
-
Lievens D, Zernecke A, Seijkens T, Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010 116 4317 4327. doi: 10.1182/blood-2010-01-261206
-
(2010)
Blood
, vol.116
, pp. 4317-4327
-
-
Lievens, D.1
Zernecke, A.2
Seijkens, T.3
-
37
-
-
0036130828
-
CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism
-
André P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD, CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002 8 247 252. doi: 10.1038/nm0302-247
-
(2002)
Nat Med
, vol.8
, pp. 247-252
-
-
André, P.1
Prasad, K.S.2
Denis, C.V.3
He, M.4
Papalia, J.M.5
Hynes, R.O.6
Phillips, D.R.7
Wagner, D.D.8
-
38
-
-
0033965079
-
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
-
Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB, Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000 6 114. doi: 10.1038/72162
-
(2000)
Nat Med
, vol.6
, pp. 114
-
-
Kawai, T.1
Andrews, D.2
Colvin, R.B.3
Sachs, D.H.4
Cosimi, A.B.5
-
39
-
-
84933042246
-
Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase β, and Not Via CD40 and IκB Kinase
-
Kuijpers MJ, Mattheij NJ, Cipolla L, van Geffen JP, Lawrence T, Donners MM, Boon L, Lievens D, Torti M, Noels H, Gerdes N, Cosemans JM, Lutgens E, Heemskerk JW, Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase β and Not Via CD40 and IκB Kinase Arterioscler Thromb Vasc Biol 2015 35 1374 1381. doi: 10.1161/ATVBAHA.114.305127
-
(2015)
Arterioscler Thromb Vasc Biol
, vol.35
, pp. 1374-1381
-
-
Kuijpers, M.J.1
Mattheij, N.J.2
Cipolla, L.3
Van Geffen, J.P.4
Lawrence, T.5
Donners, M.M.6
Boon, L.7
Lievens, D.8
Torti, M.9
Noels, H.10
Gerdes, N.11
Cosemans, J.M.12
Lutgens, E.13
Heemskerk, J.W.14
-
40
-
-
0032484987
-
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
-
Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 591 594. doi: 10.1038/35393
-
(1998)
Nature
, vol.391
, pp. 591-594
-
-
Henn, V.1
Slupsky, J.R.2
Gräfe, M.3
Anagnostopoulos, I.4
Förster, R.5
Müller-Berghaus, G.6
Kroczek, R.A.7
-
41
-
-
0035883087
-
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40
-
Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA, The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001 98 1047 1054
-
(2001)
Blood
, vol.98
, pp. 1047-1054
-
-
Henn, V.1
Steinbach, S.2
Büchner, K.3
Presek, P.4
Kroczek, R.A.5
-
42
-
-
81255143017
-
Arterial thrombosis-insidious, unpredictable and deadly
-
Jackson SP, Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 2011 17 1423 1436. doi: 10.1038/nm.2515
-
(2011)
Nat Med
, vol.17
, pp. 1423-1436
-
-
Jackson, S.P.1
-
43
-
-
0034019601
-
Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions
-
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000 20 1262 1275
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 1262-1275
-
-
Virmani, R.1
Kolodgie, F.D.2
Burke, A.P.3
Farb, A.4
Schwartz, S.M.5
-
44
-
-
59649100859
-
Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases
-
van Gils JM, Zwaginga JJ, Hordijk PL, Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009 85 195 204. doi: 10.1189/jlb.0708400
-
(2009)
J Leukoc Biol
, vol.85
, pp. 195-204
-
-
Van Gils, J.M.1
Zwaginga, J.J.2
Hordijk, P.L.3
-
45
-
-
33845334214
-
Risk stratification of patients with acute myocardial infarction by quantification of circulating monocyte-platelet aggregates
-
Lippi G, Montagnana M, Salvagno GL, Cicorella N, Degan M, Minuz P, Lechi C, Guidi GC, Risk stratification of patients with acute myocardial infarction by quantification of circulating monocyte-platelet aggregates. Int J Cardiol 2007 115 101 102. doi: 10.1016/j.ijcard.2005.12.017
-
(2007)
Int J Cardiol
, vol.115
, pp. 101-102
-
-
Lippi, G.1
Montagnana, M.2
Salvagno, G.L.3
Cicorella, N.4
Degan, M.5
Minuz, P.6
Lechi, C.7
Guidi, G.C.8
-
46
-
-
84877755222
-
Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab-preclinical and clinical studies
-
Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C, Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab-preclinical and clinical studies. Thromb Res 2013 131 401 410. doi: 10.1016/j.thromres.2013.02.020
-
(2013)
Thromb Res
, vol.131
, pp. 401-410
-
-
Kling, D.1
Stucki, C.2
Kronenberg, S.3
Tuerck, D.4
Rhéaume, E.5
Tardif, J.C.6
Gaudreault, J.7
Schmitt, C.8
-
47
-
-
84862670355
-
An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes
-
Maugeri N, Rovere-Querini P, Evangelista V, An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS One 2012 7 e39484. doi: 10.1371/journal.pone.0039484
-
(2012)
PLoS One
, vol.7
, pp. e39484
-
-
Maugeri, N.1
Rovere-Querini, P.2
Evangelista, V.3
-
48
-
-
79961097307
-
+ T-cell differentiation via multiple chemokines in humans
-
+ T-cell differentiation via multiple chemokines in humans. Thromb Haemost 2011 106 353 362. doi: 10.1160/TH11-01-0020
-
(2011)
Thromb Haemost
, vol.106
, pp. 353-362
-
-
Gerdes, N.1
Zhu, L.2
Ersoy, M.3
Hermansson, A.4
Hjemdahl, P.5
Hu, H.6
Hansson, G.K.7
Li, N.8
-
49
-
-
0025939394
-
Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production
-
Hawrylowicz CM, Howells GL, Feldmann M, Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991 174 785 790
-
(1991)
J Exp Med
, vol.174
, pp. 785-790
-
-
Hawrylowicz, C.M.1
Howells, G.L.2
Feldmann, M.3
-
50
-
-
84894541867
-
Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans
-
Beaulieu LM, Lin E, Mick E, Koupenova M, Weinberg EO, Kramer CD, Genco CA, Tanriverdi K, Larson MG, Benjamin EJ, Freedman JE, Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 2014 34 552 564. doi: 10.1161/ATVBAHA.113.302700
-
(2014)
Arterioscler Thromb Vasc Biol
, vol.34
, pp. 552-564
-
-
Beaulieu, L.M.1
Lin, E.2
Mick, E.3
Koupenova, M.4
Weinberg, E.O.5
Kramer, C.D.6
Genco, C.A.7
Tanriverdi, K.8
Larson, M.G.9
Benjamin, E.J.10
Freedman, J.E.11
-
51
-
-
78650420516
-
Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-Associated factor-2/Rac1/p38 mitogen-Activated protein kinase signaling pathway
-
Yacoub D, Hachem A, Théorêt JF, Gillis MA, Mourad W, Merhi Y, Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-Associated factor-2/Rac1/p38 mitogen-Activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 2010 30 2424 2433. doi: 10.1161/ATVBAHA.110.216143
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 2424-2433
-
-
Yacoub, D.1
Hachem, A.2
Théorêt, J.F.3
Gillis, M.A.4
Mourad, W.5
Merhi, Y.6
-
52
-
-
12144288178
-
Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation
-
Schuler W, Bigaud M, Brinkmann V, Di Padova F, Geisse S, Gram H, Hungerford V, Kleuser B, Kristofic C, Menninger K, Tees R, Wieczorek G, Wilt C, Wioland C, Zurini M, Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004 77 717 726
-
(2004)
Transplantation
, vol.77
, pp. 717-726
-
-
Schuler, W.1
Bigaud, M.2
Brinkmann, V.3
Di Padova, F.4
Geisse, S.5
Gram, H.6
Hungerford, V.7
Kleuser, B.8
Kristofic, C.9
Menninger, K.10
Tees, R.11
Wieczorek, G.12
Wilt, C.13
Wioland, C.14
Zurini, M.15
-
53
-
-
84866314973
-
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
-
Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer EA, A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012 159 58 66. doi: 10.1111/j.1365-2141.2012.09251.x
-
(2012)
Br J Haematol
, vol.159
, pp. 58-66
-
-
Bensinger, W.1
Maziarz, R.T.2
Jagannath, S.3
Spencer, A.4
Durrant, S.5
Becker, P.S.6
Ewald, B.7
Bilic, S.8
Rediske, J.9
Baeck, J.10
Stadtmauer, E.A.11
-
54
-
-
22844449094
-
Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease
-
Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL, Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005 22 111 122. doi: 10.1111/j.1365-2036.2005.02526.x
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 111-122
-
-
Kasran, A.1
Boon, L.2
Wortel, C.H.3
Hogezand, R.A.4
Schreiber, S.5
Goldin, E.6
Boer, M.7
Geboes, K.8
Rutgeerts, P.9
Ceuppens, J.L.10
|